Sanofi Agrees to Acquire Provention Bio For $2.9 billion
Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.
Reuters reported French pharmaceutical company Sanofi SA has agreed to acquire Provention Bio Inc for $2.9 billion in cash to strengthen its drug pipeline following development setbacks.
The acquisition would give Sanofi full ownership of Tzield, a drug that was approved in the United States last year for delaying the onset of the third and final stage of type 1 diabetes. The deal builds on an existing co-promotion agreement between the two companies, and Sanofi expects to complete the acquisition in the second quarter of 2023.
While Sanofi's asthma and eczema drug Dupixent are boosting sales, its drug development pipeline has been criticised as weak by investors. Provention Bio's shares nearly quadrupled in premarket trade from their last close at $6.70 after the announcement.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
